(Q50587404)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10534357%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

title

Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10534357%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

1 reference

cost-effectiveness analysis

1 reference

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10534357%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

author name string

Z M Younossi

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10534357%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

J G McHutchison

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10534357%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

K M Shermock

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10534357%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

language of work or name

English

0 references

publication date

1 November 1999

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10534357%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10534357%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

volume

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10534357%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

page(s)

1318-1324

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10534357%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10534357%20AND%20SRC:MED&resulttype=core&format=json

The long-term pathological evolution of chronic hepatitis C.

1 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300518

7 January 2021

Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300518

7 January 2021

Risk factors for hepatocellular carcinoma among patients with chronic liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300518

7 January 2021

Hepatocellular carcinoma in Italian patients with cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300518

7 January 2021

An analysis of liver transplant experience from 37 transplant centers as reported to Medicare.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300518

7 January 2021

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300518

7 January 2021

Therapy of hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300518

7 January 2021

Predictors of sustained response, relapse and no response in patients with chronic hepatitis C treated with interferon-alpha

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300518

7 January 2021

Factors predictive of the response to interferon in patients with chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300518

7 January 2021

Histopathology of hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300518

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300518

7 January 2021

A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300518

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300518

7 January 2021

Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300518

7 January 2021

Compensated cirrhosis: Natural history and prognostic factors

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300518

7 January 2021

Prognosis after the first episode of gastrointestinal bleeding or coma in cirrhosis. Survival and prognostic factors

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300518

7 January 2021

Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300518

7 January 2021

Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300518

7 January 2021

10-Year follow-up after interferon-alpha therapy for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300518

7 January 2021

Cost-effectiveness of interferon-alpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300518

7 January 2021

The impact of age on the cost-effectiveness of hypertension treatment: an analysis of randomized drug trials.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300518

7 January 2021

Cost effectiveness of vaccination against pneumococcal pneumonia: an update

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300518

7 January 2021

Screening blood donors for human immunodeficiency virus antibody: cost-benefit analysis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300518

7 January 2021

Screening for breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300518

7 January 2021

Cost-effectiveness of extending screening mammography guidelines to include women 40 to 49 years of age.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300518

7 January 2021

Cost effectiveness of colorectal cancer screening in the elderly

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300518

7 January 2021

Identifiers

DOI

10.1002/HEP.510300518

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10534357%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

1 reference